BOULDER, Colo., Sept. 17 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
The new grant award will be used to perform preclinical toxicology studies, required by the Food and Drug Administration for filing an Investigational New Drug application, to begin testing Bolder BioTechnology, Inc.'s long-acting EPO analog in people.
The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
SOURCE Bolder BioTechnology, Inc.
CONTACT: Joe Cox, Ph.D., President of Bolder BioTechnology, Inc.,
+1-303-420-4420, ext. 202
Web site: http://www.bolderbio.com/